Entering text into the input field will update the search result below

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q1 2020 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2020 Earnings Conference Call May 6, 2020 8:30 AM ET

Company Participants

John Bluth - Senior Vice President, Investor Relations and Corporate Communications

Jon Stonehouse - President and Chief Executive Officer

Charlie Gayer - Chief Commercial Officer

Megan Sniecinski - Chief Business Officer

William Sheridan - Chief Medical Officer

Anthony Doyle - Chief Financial Officer

Conference Call Participants

Jessica Fye - JPMorgan

Gena Wang - Barclays PLC

Tyler Van Buren - Piper Sandler

Liisa Bayko - JMP Securities LLP

Serge Belanger - Needham & Company

Maury Raycroft - Jefferies Group LLC


Good morning, ladies and gentlemen. And welcome to the BioCryst First Quarter 2020 Earnings Call. At this time, all the participant lines are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Mr. John Bluth at BioCryst.

John Bluth

Thanks, Whitney. Good morning and welcome to BioCryst first quarter 2020 corporate update and financial results conference call. Today’s press release and slides are available on our website.

Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Medical Officer, Dr. Bill Sheridan; Chief Business Officer, Megan Sniecinski; and Chief Commercial Officer, Charlie Gayer. Following our remarks, we will answer your questions.

Before we begin, please note that today’s conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company’s future performance and/or achievements.

These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should

Recommended For You

Comments (6)

yazzbro profile picture
I don't know...they say they have cash but, are also looking to dilute $500M with stock. A lot of big talk from the CEO but, that possible dilution makes me pause a bit. And yes it is just shares on the shelf but, they will use them eventually to further develop their pipeline..I don't know. It really comes down to the COVID drug.. If you get good results there then that could send shares soaring and then watch for a dilution. Diluting now while the shares are still in the $3 to $4 range would be silly...But I don't know. I guess we see..
xXgodFatherXx profile picture
That makes no sense. They would not use the entire shelf filing all at once. They never have.
Low cash for next Q
xXgodFatherXx profile picture
$114 million on hand with $22 million from Torii coming at any point, plus they are looking to partner with their potential monotherapeutic Berotralstat,and let's not even get started with Galidesivir being a front runner for Covid19 after data release in Brazil which they are not looking to add a 4th site for the trial. Oh and if Galidesivir is proven successful with efficacy and safety BARDA and NIAID could bring more cash to their existing relationship with Biocryst? You talking about this company? GTFOJ
xXgodFatherXx profile picture
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About BCRX

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BCRX

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.